JAK2-V617F mutation analysis of granulocytes and platelets from patients with chronic myeloproliferative disorders: Advantage of studying platelets

British Journal of Haematology

Volumn 139, Issue 1, 2007, Pages 64-69

  Toyama, Kohtaro ^b   Karasawa, Masamitsu ^b   Yamane, Arito ^b   Irisawa, Hiroyuki ^b   Yokohama, Akihiko ^b   Saitoh, Takayuki ^b   Handa, Hiroshi ^b   Matsushima, Takafumi ^b   Sawamura, Morio ^c   Miyawaki, Shuichi ^d   Murakami, Hirokazu ^b   Nojima, Yoshihisa ^b   Tsukamoto, Norifumi ^a,b  

^a GUNMA UNIVERSITY   (Japan)

^b GUNMA UNIVERSITY   (Japan)

^c Shibukawa Medical Center   (Japan)

^d SAISEIKAI MAEBASHI HOSPITAL   (Japan)

Author keywords

Chronic myeloproliferative disorder; Essential thrombocythaemia; JAK2 V617F; Molecular diagnosis; Polycythaemia vera; Primary myelofibrosis

Indexed keywords

JANUS KINASE 2;

ARTICLE; BLOOD ANALYSIS; BLOOD CELL COUNT; CLINICAL FEATURE; CONTROLLED STUDY; GENE MUTATION; GENE SEQUENCE; GRANULOCYTE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MYELOPROLIFERATIVE DISORDER; POLYCYTHEMIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; THROMBOCYTE; THROMBOCYTHEMIA;

ADULT; AGED; AGED, 80 AND OVER; BLOOD PLATELETS; CHRONIC DISEASE; DNA MUTATIONAL ANALYSIS; FEMALE; GRANULOCYTES; HUMANS; JANUS KINASE 2; LEUKOCYTE COUNT; MALE; MIDDLE AGED; MOLECULAR DIAGNOSTIC TECHNIQUES; MUTATION; MYELOFIBROSIS; MYELOPROLIFERATIVE DISORDERS; POLYCYTHEMIA VERA; RISK; STATISTICS, NONPARAMETRIC; T-LYMPHOCYTES; THROMBOCYTHEMIA, HEMORRHAGIC; THROMBOSIS;

EID: 34548573167     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2007.06755.x     Document Type: Article

References (27)

1. Adamson, J.W., Fialkow, P.J., Murphy, S., Prchal, J.F. Steinmann, L. (1976) Polycythemia vera: stem-cell and probable clonal origin of the disease. New England Journal of Medicine, 295, 913 916.
2. Antonioli, E., Guglielmelli, P., Pancrazzi, A., Bogani, C., Verrucci, M., Ponziani, V., Longo, G., Bosi, A. Vannucchi, A.M. (2005) Clinical implications of the JAK2-V617F mutation in essential thrombocythemia. Leukemia, 19, 1847 1849.
3. Arellano-Rodrigo, E., Alvarez-Larran, A., Reverter, J.C., Villamor, N., Colomer, D. Cervantes, F. (2006) Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status. Haematologica, 91, 169 175
4. Baxter, E.J., Scott, L.M., Campbell, P.J., East, C., Fourouclas, N., Swanton, S., Vassiliou, G.S., Bench, A.J., Boyd, E.M., Curtin, N., Scott, M.A., Erber, W.N. Green, A.R. (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet, 365, 1054 1061.
5. Bellosillo, B., Martinez-Aviles, L., Gimeno, E., Florensa, L., Longaron, R., Navarro, G., Salar, A., Espinet, B., Sole, F., Serrano, S. Besses, C. (2007) A higher JAK2 V617F-mutated clone is observed in platelets than in granulocytes from essential thrombocythemia patients, but not in patients with polycythemia vera and primary myelofibrosis. Leukemia, 21, 1331 1332.
6. Campbell, P.J., Scott, P.M., Buck, G., Wheatley, K., East, C.L., Marsden, J.T., Duffy, A., Boyd, E.M., Bench, A.J., Scott, M.A., Vassiliou, G.S., Milligan, D.W., Smith, S.R., Erber, W.N., Bareford, D., Wilkins, B.S., Reilly, J.T., Harrison, C.N. Green, A.R. (2005) Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2-V617F mutation status: a prospective study. Lancet, 366, 1945 1953.
7. Cheung, B., Radia, D., Pantelidis, P., Yadegarfar, G. Harrison, C. (2006) The presence of the JAK2 V617F mutation is associated with a higher haemoglobin and increased risk of thrombosis in essential thrombocythaemia. British Journal of Haematology, 132, 244 245.
8. Ferraris, A.M., Mangerini, R., Racchi, O., Rapezzi, D., Rolfo, M., Casciaro, S. Gaetani, G.F. (1999) Heterogeneity of clonal development in chronic myeloproliferative disorders. American Journal of Hematology, 60, 158 160.
9. Finazzi, G., Rambaldi, A., Guerini, V., Carobbo, A. Barbui, T. (2007) Risk of thrombosis in patients with essential thrombocythemia and polycythemia vera according to JAK2 V617F mutation status. Haematologica, 92, 135 136.
10. Gale, R.E., Allen, A.J., Nash, M.J. Linch, D.C. (2007) Long-term serial analysis of X-chromosome inactivation patterns and JAK2-V617F mutant levels in patients with essential thrombocythemia show that minor mutant-positive clones can remain stable for many years. Blood, 109, 1241 1243.
11. Gilliland, D.G., Blanchard, K.L., Levy, J., Perrin, S. Bunn, H.F. (1991) Clonality in myeloproliferative disorders: analysis by means of the polymerase chain reaction. Proceedings of the National Academy of Science of the United States of America, 88, 6848 6852.
12. Harrison, C.N., Gale, R.E., Machin, S.J. Linch, D.C. (1999) A large proportion of patients with a diagnosis of essential thrombocythemia do not have a clonal disorder and may be at lower risk of thrombotic complications. Blood, 93, 417 424.
13. Heller, P.G., Lev, P.R., Salim, J.P., Kornblihtt, L.I., Goette, N.P., Chazarreta, C.D., Glembotsky, A.C., Vassallu, P.S., Marta, R.F. Molinas, F.C. (2006) JAK2V617F mutation in platelets from essential thrombocythemia patients: correlation with clinical features and analysis of STAT5 phosphorylation status. European Journal of Haematololgy, 77, 210 216.
14. James, C., Ugo, V., LeCouédic, J.P., Staerk, J., Delhommeau, F., Lacout, C., Garçon, L., Raslova, H., Berger, R., Bennaceur-Griscelli, A., Villeval, J.L., Constantinescu, S.N., Casadevall, N. Vainchenker, W. (2005) A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature, 434, 1144 1148.
15. el-Kassar, N., Hetet, G., Briere, J. Grandchamp, B. (1997) Clonality analysis of haematopoiesis in essential thrombocythemia: advantages of studying T lymphocytes and platelets. Blood, 89, 128 134.
16. Kiladjian, J.J., Elkassar, N., Cassinat, B., Hetet, G., Giraudier, S., Balitrand, N., Conejero, C., Briere, J., Fenaux, P., Chomienne, C. Grandchamp, B. (2006) Essential thrombocythemias without-V617F JAK2 mutation are clonal haematopoietic stem cell disorders. Leukemia, 20, 1181 1183.
17. Kralovics, R., Passamonti, F., Buser, A.S., Teo, S.S., Tiedt, R., Passweg, J.R., Tichelli, A., Cazzola, M. Skoda, R.C. (2005) A gain-of-function mutation of JAK2 in myeloproliferative disorders. New England Journal of Medicine, 352, 1779 1790.
18. Kralovics, R., Teo, S., Li, S., Theocharides, A., Buser, S., Tichelli, A. Skoda, C. (2006) Acquisition of the V617F-mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders. Blood, 108, 1377 1380.
19. Levine, R.L., Wadleigh, M., Cools, J., Ebert, B.L., Wernig, G., Huntly, B.J., Boggon, T.J., Wlodarska, I., Clark, J.J., Moore, S., Adelsperger, J., Koo, S., Lee, J.C., Gabriel, S., Mercher, T., D'Andrea, A., Fröhling, S., Döhner, K., Marynen, P., Vandenberghe, P., Mesa, R.A., Tefferi, A., Griffin, J.D., Eck, M.J., Sellers, W.R., Meyerson, M., Golub, T.R., Lee, S.J. Gilliland, D.G. (2005) Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell, 7, 387 397.
20. Levine, R.L., Belisle, C., Wadleigh, M., Zahrieh, D., Lee, S., Chagnon, P., Gilliland, D.G. Busque, L. (2006) X-inactivation-based clonality analysis and quantitative JAK2V617F assessment reveal a strong association between clonality and JAK2V617F in PV but not ET/MMM, and identifies a subset of JAK2V617F-negative ET and MMM patients with clonal haematopoiesis. Blood, 107, 4139 4141.
21. Moliterno, A.R., Williams, D.M., Rogers, O. Spivak, J.L. (2006) Molecular mimicry in the chronic myeloproliferative disorders: reciprocity between quantitative JAK2-V617F and Mpl expression. Blood, 108, 3913 3915,.
22. Pardanani, A.D., Levine, R.L., Lasho, T., Pikman, Y., Mesa, R.A., Wadleigh, M., Steensma, D.P., Elliott, M.A., Wolanskyj, A.P., Hogan, W.J., McClure, R.F., Litzow, M.R., Gilliland, D.G. Tefferi, A. (2006) MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood, 108, 3472 3476.
23. Scott, L.M., Tong, W., Levine, R.L., Scott, M.A., Beer, P.A., Stratton, M.R., Futreal, P.A., Erber, W.N., McMullin, M.F., Harrison, C.N., Warren, A.J., Gilliland, D.G., Lodish, H.F. Green, A.R. (2007) JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. New England Journal of Medicine, 356, 459 468.
24. Shih, L.Y., Lin, T.L., Lai, C.L., Dunn, P., Wu, J.H., Wang, P.N., Kuo, M.C. Lee, L.C. (2002) Predictive values of X-chromosome inactivation patterns and clinicohematologic parameters for vascular complications in female patients with essential thrombocythemia. Blood, 100, 1596 1601.
25. Spivak, J.L. (2004) The chronic myeloproliferative disorders: clonality and clinical heterogeneity. Seminars in Hematology, 41 (Suppl. 3 1 5.
26. Vardiman, J.W., Harris, N.L. Brunning, R.D. (2002) The World Health Organization (WHO) classification of the myeloid neoplasms. Blood, 100, 2292 2302.
27. Wolanskyj, A.P., Lasho, T.L., Schwager, S.M., McClure, R.F., Wadleigh, M., Lee, S.J., Gilliland, D.G. Tefferi, A. (2005) JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance. British Journal of Haematology, 131, 208 213.